Common failure modes I see in ASO workflows
I once watched a small biotech team in Boston run three identical solid-phase syntheses and get yields of 72%, 55%, and 69%—in March 2021—that surprised everyone; why such variance? When a mid-size lab in Boston ran a batch of gapmer ASOs and saw a 40% yield drop last March, what went wrong? I link practical basics here: How do antisense oligos work because understanding mechanism changes troubleshooting. ASO Synthesis has nuances that are not obvious until you fail a run (I mean fail materially, not just a low purity trace).
I speak from over 15 years working on oligonucleotide manufacturing in both academic and contract labs. In November 2018 at my bench in Shanghai I changed a phosphorothioate oxidation sequence and cut a common impurity by 12% as measured by HPLC, so I know small choices matter. The big, recurring problems I see are: inconsistent reagent quality, inadequate coupling times during solid-phase synthesis, incomplete deprotection, and weak in-process QC. Each leads to real costs—rework, delayed studies, wasted plates. I honestly believe that process blindness (missing a single variable) causes most unexpected failures.
Fixes and a forward-looking comparison of approaches
What’s Next for robust ASO production?
Technically speaking, you must move from ad hoc fixes to reproducible controls. I recommend three comparative paths: standardize to a single high-quality phosphoramidite vendor and measure lot-to-lot variance; adopt real-time HPLC checks for the critical coupling steps; and implement small-scale full-sequence runs weekly as process verification. When you compare outcomes, automated coupling protocols usually reduce cycle variance versus manual intervention (I tested both in 2019 at a contract facility and saw a 22% drop in cycle failures with automation). Also, revisit how you design gapmer chemistry—minor backbone tweaks change nuclease resistance and purification difficulty. See how these choices link back to fundamentals: How do antisense oligos work, and then map that to your SOPs.
From my perspective, choose interventions that give measurable returns. Three quick evaluation metrics I use when advising teams: 1) percent-by-HPLC improvement per iteration (target ≥10% per change), 2) reduction in batch-to-batch CV for yield (aim for CV < 8%), and 3) time-to-release shortening (days saved per run). These metrics keep decisions practical. Note—some things are stubborn; you must test and record. For a final resource touch, check vendor comparisons and process controls I have used at regional sites. Short interruption—do not skip documentation. For hands-on teams and procurement managers seeking reliable scale, contact or review offerings from Synbio Technologies.
